(2S,3R,4S,5S,6R)-2-[1-ethyl-5-methyl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2S,3R,4S,5S,6R)-2-[1-ethyl-5-methyl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
• 化学式: C₂₂H₃₂N₂O₇
• 分子量: 436.5
• InChiKey: LYUBJYPLHJGTOJ-JPVHLGFFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1782828A1

  公开（公告）日：2007-05-09

  The present invention provides pharmaceutical compositions useful as agents for the inhibition of progression of diseases associated with abnormal accumulation ofliverlipids. In particular, the pharmaceutical compositions of the present invention which comprise as an active ingredient a sodium/glucose co-transporter 2 inhibitor are highly suitable as an agent for the inhibition of progression of not only common fatty liver but also non-alcholic fatty liver disease (NAFL), non-alcholic steatohepatitis (NASH), hypernutritive fatty liver, diabetic fatty liver, alcholic fatty liver disease toxic fatty liver or the like.

  本发明提供的药物组合物可作为抑制与肝脂异常积聚有关的疾病进展的药物。特别是，本发明的药物组合物包含钠/葡萄糖共转运体 2 抑制剂作为活性成分，非常适合作为不仅是普通脂肪肝，而且是非胆汁性脂肪肝（NAFL）、非胆汁性脂肪性肝炎（NASH）、高营养脂肪肝、糖尿病脂肪肝、胆汁性脂肪肝中毒性脂肪肝或类似疾病的进展抑制剂。
• Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat
  申请人：Katsuno Kenji

  公开号：US20080045466A1

  公开（公告）日：2008-02-21

  The present invention provides pharmaceutical compositions useful as agents for the inhibition of progression of diseases associated with abnormal accumulation of liver lipids. In particular, the pharmaceutical compositions of the present invention which comprise as an active ingredient a sodium/glucose co-transporter 2 inhibitor are highly suitable as an agent for the inhibition of progression of not only common fatty liver but also non-alcholic fatty liver disease (NAFL), non-alcholic steatohepatitis (NASH), hypernutritive fatty liver, diabetic fatty liver, alcholic fatty liver disease toxic fatty liver or the like.
• US8951976B2
  申请人：——

  公开号：US8951976B2

  公开（公告）日：2015-02-10